Exercise or conversion by Klemp Walter V of 14717 shares of Moleculin Biotech subject to Rule 16b-3

MBRX
 Stock
  

USD 1.12  0.03  2.61%   

Moleculin investor sentiment overview provides quick insight into current market opportunities from investing in Moleculin Biotech CS. The current market sentiment together Moleculin Biotech's historical and current headlines can help investors to time the market. Many technical investors use Moleculin Biotech stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Additionally, see Moleculin Biotech Hype Analysis, Moleculin Biotech Correlation and Moleculin Biotech Performance.
  
Moleculin Biotech stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Moleculin daily returns and investor perception about the current pice of Moleculin Biotech CS as well as its diversification or hedging effects on your existing portfolios.
Filed transaction by Moleculin Biotech Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Read at macroaxis.com
Moleculin insider trading alert for exercise of restricted stock units by Klemp Walter V, CEO and President, on 15th of July 2022. This event was filed by Moleculin Biotech Inc with SEC on 2022-07-15. Statement of changes in beneficial ownership - SEC Form 4

Moleculin Biotech Investor Sentiment by Other News Outlets

Moleculin Biotech Fundamental Analysis

We analyze Moleculin Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moleculin Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moleculin Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Probability Of Bankruptcy

Probability Of Bankruptcy Comparative Analysis

Moleculin Biotech is currently under evaluation in probability of bankruptcy category among related companies. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Moleculin Biotech Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Moleculin Biotech stock to make a market-neutral strategy. Peer analysis of Moleculin Biotech could also be used in its relative valuation, which is a method of valuing Moleculin Biotech by comparing valuation metrics with similar companies.
Additionally, see Moleculin Biotech Hype Analysis, Moleculin Biotech Correlation and Moleculin Biotech Performance. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.